A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

NCT00358683 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Certolizumab pegol

Sponsor

UCB Pharma